In a 26-0 vote, the Food and Drug Administration’s arthritis advisory committee recommended July 12 that the agency license an Amgen product as bios... More »
LONDON – Biosimilar etanercept (CHS-0214) is as effective and well tolerated as etanercept (Enbrel) for the treatment of rheumatoid arthritis accord... More »
LONDON – ABT-494 and filgotinib – two investigational and highly selective oral Janus kinase-1 inhibitors – are both showing promise in the trea... More »
LONDON – The European League Against Rheumatism and the European Federation of National Associations of Orthopaedics and Traumatology have joined fo... More »
LONDON – Retinopathy in patients taking long-term hydroxychloroquine for rheumatic conditions requires assessment by those experienced with speciali... More »
Now that the interleukin-17 inhibitor secukinumab and tumor necrosis factor inhibitors are competing options for treatment of patients with ankylosing... More »
Among patients with immune-mediated diseases and a history of malignancy, cancer recurrence rates were similar regardless of whether they received tum... More »
LONDON – Patients with ankylosing spondylitis who remained on long-term treatment with a nonsteroidal anti-inflammatory drug and a tumor necrosis fa... More »
The interleukin-6 inhibitor tocilizumab (Actemra) substantially reduced skin thickening in patients with systemic sclerosis in the “proof-of concept... More »
LONDON – Patients with psoriatic arthritis appear less likely to achieve a good response to their first anti-tumor necrosis factor therapy if they a... More »
